It elucidates the molecular mechanisms by which KIAA1429 promotes malignant phenotypes through m6A-dependent regulation of target genes, while also evaluating its potential as a novel therapeutic target for NSCLC treatment. This evidence concerns the gene VIRMA and non-small cell lung carcinoma.